Recent

% | $
Quotes you view appear here for quick access.

Neurocrine Biosciences Inc. Message Board

patworth123 33 posts  |  Last Activity: 22 hours ago Member since: Oct 20, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    VRX up 2% on the TSE today

    by kontente 23 hours ago
    patworth123 patworth123 22 hours ago Flag

    It fluctuated on Friday and although off its high for the day still closed up over 5%, so I'm not sure where you get your closed down version. The day traders will push it down at the end of the day and before the long weekend to take their profits, regardless it is well off its recent low and the trend is currently our friend. And Thanks Kon for the note about Canada.

    Sentiment: Strong Buy

  • Reply to

    Waiting on Zika approval

    by sonomaca May 28, 2016 10:26 AM
    patworth123 patworth123 May 29, 2016 5:21 PM Flag

    You all need to read the article I posted earlier..its not just about mosquitos anymore if it is also sexually transmitted then there is a whole new game in the making;
    This is a bit unnerving, but indicative of how important testing is;
    http://time.com/4343056/pregnant-women-united-states-zika/?xid=newsletter-brief

  • patworth123 by patworth123 May 29, 2016 10:55 AM Flag

    This is a bit unnerving, but indicative of how important testing is;
    http://time.com/4343056/pregnant-women-united-states-zika/?xid=newsletter-brief

    Sentiment: Strong Buy

  • Reply to

    forget ASCO

    by kajalnp May 27, 2016 3:38 PM
    patworth123 patworth123 May 27, 2016 8:23 PM Flag

    Clever find. Thank you.

    Sentiment: Strong Buy

  • Reply to

    volume

    by patworth123 May 13, 2016 12:27 PM
    patworth123 patworth123 May 13, 2016 1:08 PM Flag

    Keep dreaming, it works for me. I'm in it for the long term with a pretty big block over several accounts, and even if it drifts back into the $7's if the market has another pull back and fear moves some to the sidelines it will just create an opportunity for big block buyers to accumulate. Insiders are holding tightly to the shares they have so far. If this mentality persists, its a clear indication to me they know the value of their shares will continue to increase. The trend is our friend. Sweet dreams, Rick.

  • patworth123 by patworth123 May 13, 2016 12:27 PM Flag

    Perhaps today we are seeing a fund or 2 moving into position.

    Sentiment: Strong Buy

  • Reply to

    OT

    by chart_watcher99 May 13, 2016 9:46 AM
    patworth123 patworth123 May 13, 2016 12:19 PM Flag

    I absolutely agree, sometimes panic mode is inspirational. I look mostly at biotech with exceptional science and bought exel when it looked like it would die. If you look to those look at FATE. I have a hard time with telecom/tech since I see competition from so many angles and my clear lack of understanding of any of the technology or its applications, but I can read medical research all day long and understand a fair percent. I do also like CGEN (also out of Israel). Its been pretty beat up - my basis is in the $2 range and it went up to low teens and now settled back around $6.50, but I see it moving again soon. So refreshing there's a group on a board who communicate intelligently.

  • Reply to

    OT

    by chart_watcher99 May 13, 2016 9:46 AM
    patworth123 patworth123 May 13, 2016 12:02 PM Flag

    I'm in EXEL for the long haul. Started in 12/14 at $1.32 and total basis now about $2.30. I think its just getting started and worth a buy for the long term.

    Sentiment: Strong Buy

  • Reply to

    I see 15.00 per share.

    by rick60930 May 12, 2016 11:17 AM
    patworth123 patworth123 May 13, 2016 11:38 AM Flag

    OK you cheerleaders are pretty funny. This is the hard part, though, with an original basis of about $2.75 and a bunch of shares which is now growing in the percentage of overall value relative to the old nest egg, I added even more yesterday. I've been sitting on a bit of cash and after listening to your banter wonder whether I should buy a little more today or wait a day or 2 to see if I can get in back around $7. Perhaps those days are long gone.

    Sentiment: Strong Buy

  • Reply to

    orphan drug approval EU

    by patworth123 May 10, 2016 2:47 PM
    patworth123 patworth123 May 11, 2016 11:40 AM Flag

    I have no problem with articulate thoughtful differences of opinion. But I was raised with the following ethic; We pray for the power to be kind, the strength to be forgiving, the patience to be understanding. We put our trust in the power of good to overcome evil, the power of love to overcome hatred and we pray for a world free from violence and war. Help us to devote our life, thought, and energy to the task of making peace. When someone speaks the way you do I cannot believe you are decent, kind, thoughtful, or have many friends and I kind of feel a bit sorry for you. And now, will ignore all future outbursts.

  • Reply to

    orphan drug approval EU

    by patworth123 May 10, 2016 2:47 PM
    patworth123 patworth123 May 10, 2016 5:33 PM Flag

    Oh my somebody got up on the wrong side of the bed this morning..or perhaps the wrong side of life. I think your parents forgot the lessons about manners, respect, compassion, humanity..perhaps you should grab a seat behind Trump.

  • Reply to

    First close above $5 since Jan 6th.

    by enabeler May 10, 2016 4:20 PM
    patworth123 patworth123 May 10, 2016 5:30 PM Flag

    If we can stay over $5 for the next month or so may see some of the biotech and healthcare funds stepping in and that can help keep the "traders" from manipulating. Its likely they will buy in for the longer term.

    Sentiment: Strong Buy

  • patworth123 by patworth123 May 10, 2016 2:47 PM Flag

    from the news today; The European Commission has granted eye care company pSivida ($PSDV) an orphan medicinal product designation for its Medidur, which is used to treat chronic noninfectious uveitis.

    The designation gives pSivida up to 10 years of market exclusivity in Europe following marketing approval as well as access to the EU’s centralized marketing authorization procedure and other regulatory and financial incentives. The company said it plans to file for European marketing approval for Medidur based on results from its first Phase III trial that met its primary efficacy endpoint with a high statistical significance and achieved positive safety results.

    Sentiment: Buy

  • Reply to

    Sentiments?

    by redcoatwright May 6, 2016 8:13 AM
    patworth123 patworth123 May 6, 2016 1:36 PM Flag

    If you like the long view, then you can either average in over the next few weeks/months or just buy and wait and stop trading in and out for nickels and dimes. There is no way an individual can "predict". Even the best chartists can not chart a small biotech with any accuracy- way to many factors. If it gets over $5 and holds that line you will see the funds stepping up to the plate. Many can't touch something under $5. You can not, right now, predict market volatility or when someone might decide EXEL would make a nice asset and just offer $15 a share.

  • Reply to

    Zika/ Brazil

    by cometfinder May 5, 2016 9:20 AM
    patworth123 patworth123 May 5, 2016 5:25 PM Flag

    good points- all. I was thinking about blood transfusions - thanks for that note. In it for the long term. There are many points of profit for CEMI and ignored by many until the guillotine falls and the tests become standard.

  • Reply to

    Zika/ Brazil

    by cometfinder May 5, 2016 9:20 AM
    patworth123 patworth123 May 5, 2016 1:00 PM Flag

    I think the simplicity of the announcement without speculation was both wise and deliberate. There are many advantages to releasing the POC test outside of the US as it allows the results to then become part of the "study group" population without the expense or time of running a US clinical trial. Their relationship with Fiocruz, the potential threat the health care community anticipates from Zika, as well as the pressure with the Olympics ramping up visits to highly affected areas are all compelling reasons to sit tight. Combination tests can come along, but at the moment a quick reliable diagnostic for this is news-worthy!

  • Reply to

    ASK YOUR DOCTOR ABOUT -

    by maxx22xx Apr 26, 2016 3:39 PM
    patworth123 patworth123 Apr 28, 2016 11:54 AM Flag

    Thank you. I've been a health care practitioner (retired) in pediatrics and a microbiologist and have had multiple friends, patients, and family members afflicted by many forms of cancer (just lost the 9 year old son of a friend die).. sat through radiation treatment sessions, chemo infusions, watched a friend involved in a clinical trial for now a marketed product that extended his "death sentence" window of 4-6 weeks to almost a year, and sat up all night with friends sick from treatment. People do so many things to themselves and then expect a pill to remedy the problem. There is a big picture here, and if one is going to invest in biotech stocks it does help to comprehend the issues, market size, and some of the science.

  • Reply to

    ASK YOUR DOCTOR ABOUT -

    by maxx22xx Apr 26, 2016 3:39 PM
    patworth123 patworth123 Apr 27, 2016 11:05 AM Flag

    Chemotherapy treatment is unrelated to advertising. The uses will be determined by oncologists both on and off label. In many ways this product's research is still in its infancy and its eventual total market a mystery. That said, FDA approval opens doors in every direction, and whether EXEL takes it to its goal or the company is bought out remains another mystery. Unlike many other medical interventions patients needing this treatment will die of their disease- and many will die soon. Diabetes, heart disease, and the millions of other maladies out there are not necessarily lethal in the same category as cancer, so when you look at "side-effects" those need to be put in perspective. I'm not saying people don't die from complications of diabetes or heart disease and often simple life style adjustments can affect one's life expectancy, but these cancers are deadly and failure to treat fast and with hard hitting drugs is a death sentence.. Different sand-boxes, different rules.This story is far from over.

    Sentiment: Strong Buy

  • patworth123 patworth123 Apr 26, 2016 11:55 AM Flag

    We should all also remember that there have been phase 1 trials in other forms of CA, and with approval the opportunity and incentive to advance to phase 2 trials are more likely to accelerate. It also can begin to be used as an adjunct treatment in other trials. Solid tumors, glioblastoma, NSC lung cancer etc and partners come knocking. Oral formulations are an asset.

  • Reply to

    NEWS expected!

    by godhairyballs Apr 21, 2016 9:46 AM
    patworth123 patworth123 Apr 21, 2016 1:46 PM Flag

    The primary endpoint is 17 months which from the completion of enrollment in 11/14 would be just about now for all patients. Have incomplete results is less compelling, so my guess is the FDA is waiting for the final numbers. Often that's six months after completion - which puts it to October, but perhaps this will be faster. There are no results posted on clinical trials, and preparing the data for submission takes time as does putting it on the FDA's calendar. They want the data complete.

NBIX
49.6932+3.5032(+7.58%)10:48 AMEDT